Managing menopause in an irradiated pelvis - uncharted territory.
Sally DarnboroughPublished in: Post reproductive health (2024)
Radiotherapy is an effective cancer treatment, particularly for pelvic tumours. The number of patients with pelvic cancer being diagnosed and successfully treated is growing. Radiotherapy to the pelvis causes lasting side-effects collectively referred to as pelvic radiation disease (PRD), including bowel, bladder, sexual dysfunction, vaginal and cervical stenoses, and menopause. There is growing interest in management of menopause in cancer survivors, with the primary focus on the oncologic risk of hormone replacement therapy (HRT). Research examining if the modality with which the cancer was treated causes menopause-specific side effects is rare; however, malabsorption syndromes and anatomical changes in the pelvis post-radiotherapy may complicate effective delivery and monitoring of HRT. Consideration of these changes may significantly benefit patients in this young and growing cohort; thus, there is an urgent need to raise awareness of PRD among all clinicians, including those providing menopause care.
Keyphrases
- rectal cancer
- locally advanced
- postmenopausal women
- early stage
- replacement therapy
- papillary thyroid
- radiation induced
- end stage renal disease
- radiation therapy
- newly diagnosed
- palliative care
- squamous cell
- healthcare
- ejection fraction
- childhood cancer
- chronic kidney disease
- spinal cord injury
- oxidative stress
- young adults
- prognostic factors
- peritoneal dialysis
- smoking cessation
- lymph node metastasis
- mental health
- quality improvement
- prostate cancer
- chronic pain
- affordable care act